Centessa Pharmaceuticals' General Counsel Hussain Iqbal J buys and sells 6000 shares.

Centessa Pharmaceuticals plc (CNTA) has disclosed that General Counsel Hussain Iqbal J has recently made two transactions involving shares of the company. Firstly, he purchased 6,000 shares at a price of $5.84 per share on July 15, 2025. Secondly, he sold the same number of shares at a price of $14.93 per share on the same date.

Centessa Pharmaceuticals plc (CNTA), a clinical-stage pharmaceutical company, recently disclosed significant share transactions executed by its General Counsel, Hussain Iqbal J. On July 15, 2025, Iqbal purchased 6,000 shares at $5.84 per share, and subsequently sold the same number of shares at $14.93 per share on the same date [3].

The transactions were reported under Rule 144 of the Securities Act of 1933, which governs the sale of securities by issuers and their affiliates. The sales were part of a Rule 10b5-1 trading plan, indicating a pre-established strategy for the sale of securities [3].

Centessa Pharmaceuticals plc is involved in the discovery, development, and delivery of medicines, with a focus on neurological and neurodegenerative disorders. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2 [1].

The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as well as other potential symptoms, including excessive daytime sleepiness, impaired attention, cognitive deficits, and fatigue; and ORX489 for the treatment of neuropsychiatric disorders. Additionally, it offers LockBody, designed to selectively drive potent effector function activity, such as CD3, into the tumor microenvironment [1].

Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom. The company has a Relative Strength Rating (RSR) of 81, indicating strong technical performance [2].

References:
[1] https://finance.yahoo.com/quote/CNTA/
[2] https://www.investors.com/ibd-data-stories/stocks-to-watch-centessa-pharma-adr-sees-relative-strength-rating-jump-to-81/
[3] https://www.streetinsider.com/SEC+Filings/Form++144++++++++Centessa+Pharmaceuticals+++++++++++++++Filed+by%3A+HUSSAIN+IQBAL+J/25054580.html